Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Oral mezigdomide is a cereblon-modifying agent that results in degradation of transcription factors essential for myeloma cell survival. Given with dexamethasone, it induced responses in 40% of heavily pretreated patients.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2023-09, Vol.389 (11), p.1009-1022
Hauptverfasser: Richardson, Paul G., Trudel, Suzanne, Popat, Rakesh, Mateos, María-Victoria, Vangsted, Annette J., Ramasamy, Karthik, Martinez-Lopez, Joaquín, Quach, Hang, Orlowski, Robert Z., Arnao, Mario, Lonial, Sagar, Karanes, Chatchada, Pawlyn, Charlotte, Kim, Kihyun, Oriol, Albert, Berdeja, Jesus G., Rodríguez Otero, Paula, Casas-Avilés, Ignacio, Spirli, Alessia, Poon, Jennifer, Li, Shaoyi, Gong, Jing, Wong, Lilly, Lamba, Manisha, Pierce, Daniel W., Amatangelo, Michael, Peluso, Teresa, Maciag, Paulo, Katz, Jessica, Pourdehnad, Michael, Bahlis, Nizar J.
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Oral
Adverse events
Antibodies
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers
Bone marrow
Confidence intervals
Dexamethasone
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Dexamethasone - therapeutic use
Drug dosages
Hematology
Humans
Hypotheses
Lenalidomide - adverse effects
Leukemia
Lymphocytes B
Lymphoma
Medical prognosis
Multiple myeloma
Multiple Myeloma - drug therapy
Neutropenia
Neutropenia - chemically induced
Neutrophils
Oncology
Pharmacodynamics
Pharmacokinetics
Recurrence
Schedules
Targeted cancer therapy
Treatments in Oncology
Ubiquitin-protein ligase
Ubiquitin-Protein Ligases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Oral mezigdomide is a cereblon-modifying agent that results in degradation of transcription factors essential for myeloma cell survival. Given with dexamethasone, it induced responses in 40% of heavily pretreated patients.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2303194